MCID: HYP081
MIFTS: 56

Hypolipoproteinemia

Categories: Blood diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypolipoproteinemia

MalaCards integrated aliases for Hypolipoproteinemia:

Name: Hypolipoproteinemia 11 19 75 14
Lipoprotein Deficiencies 11 53
Hypolipoproteinaemia 11 33
Lipoprotein Disorder 53 71
Dyslipidaemia, Depressed Hdl Cholesterol 33
High-Density Lipoprotein Deficiency 33
Lipoprotein Deficiency Disorder 33
High-Density Lipoid Deficiency 33
Lipoprotein Deficiency 33
Hypolipoproteinemias 43
Hypolipidaemia 33
Lipoprotein 16

Classifications:



External Ids:

Disease Ontology 11 DOID:1387
ICD9CM 34 272.5
MeSH 43 D007009
SNOMED-CT 68 363140000
ICD10 31 E78.6
UMLS 71 C0020623 C0596848

Summaries for Hypolipoproteinemia

GARD: 19 Hypolipoproteinemia refers to unusually low levels of fats (lipids) in the blood. Low lipid levels may be caused by rare genetic conditions, or be a sign of another disorder such as overactive thyroid, anemia, undernutrition, cancer, chronic infection, or impaired absorption of foods from the digestive tract. Associated genetic disorders includes abetalipoproteinemia, familial hypobetalipoproteinemia, and chylomicron retention disease. Signs and symptoms in the the genetic or familial form of Hypolipoproteinemia vary. In some forms, although the low density lipoprotein (LDL) cholesterol levels are very low, this syndrome may not cause any symptoms. Other forms result in absent or near absent LDL levels and can cause symptoms in infancy and early childhood.

MalaCards based summary: Hypolipoproteinemia, also known as lipoprotein deficiencies, is related to familial lipoprotein lipase deficiency and lipase deficiency, combined. An important gene associated with Hypolipoproteinemia is ABCA1 (ATP Binding Cassette Subfamily A Member 1), and among its related pathways/superpathways are Metabolism and Transport of inorganic cations/anions and amino acids/oligopeptides. The drugs Liraglutide and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and thyroid, and related phenotypes are Increased free cholesterol and Increased LDL uptake

Disease Ontology: 11 A lipid metabolism disorder that is characterized by unusually low levels of fats in the blood.

Wikipedia: 75 Hypolipoproteinemia, hypolipidemia, or hypolipidaemia (British English) is a form of dyslipidemia that... more...

Related Diseases for Hypolipoproteinemia

Diseases related to Hypolipoproteinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1539)
# Related Disease Score Top Affiliating Genes
1 familial lipoprotein lipase deficiency 32.3 LPL LIPG APOE APOC3 APOB APOA1
2 lipase deficiency, combined 32.2 LPL LIPG
3 abdominal obesity-metabolic syndrome 1 32.1 MTTP MIR33A LPL APOB
4 hypercholesterolemia, familial, 4 32.0 PCSK9 MTTP APOB ABCG5
5 hypercholesterolemia, familial, 2 32.0 APOE APOB
6 fish-eye disease 32.0 LCAT APOA2 APOA1
7 hyperlipoproteinemia, type i 32.0 PCSK9 MTTP LPL LIPG APOE APOC3
8 homozygous familial hypercholesterolemia 32.0 PCSK9 APOB ABCG5
9 hyperlipoproteinemia, type iii 31.9 LPL LPA CETP APOE APOB APOA1
10 apolipoprotein c-iii deficiency 31.8 LPL APOC3
11 hypercholesterolemia, familial, 1 31.8 PCSK9 LPL LPA LCAT CETP APOE
12 hyperlipoproteinemia, type v 31.7 LPL APOE APOC3 APOB APOA1 ANGPTL3
13 arteries, anomalies of 31.7 MIR33A APOE APOB APOA1
14 niemann-pick disease, type c1 31.7 ABCG5 ABCG1 ABCA1
15 hypertriglyceridemia 1 31.7 LPL CETP APOE APOC3 APOB APOA2
16 lecithin:cholesterol acyltransferase deficiency 31.6 LPL LPA LCAT CETP APOE APOB
17 platelet glycoprotein iv deficiency 31.5 SCARB1 LPL APOE APOB
18 lipoprotein quantitative trait locus 31.4 SCARB1 LPL LPA LCAT CETP APOE
19 stroke, ischemic 31.3 LPA APOE APOB ABCA1
20 hyperlipoproteinemia, type iv 31.3 LPL CETP APOE APOC3 APOB APOA1
21 type 1 diabetes mellitus 31.2 LPL APOE APOB APOA1
22 intermediate coronary syndrome 31.2 PCSK9 APOB APOA1
23 hypoalphalipoproteinemia 31.2 LPL LCAT CETP APOC3 APOB APOA2
24 cerebrovascular disease 31.2 LPL CETP APOE APOB APOA1
25 amyloidosis 31.2 LPA APOE APOA2 APOA1
26 arteriosclerosis 31.1 LPA APOE APOB APOA1
27 hyperalphalipoproteinemia 1 31.1 SCARB1 LPL LCAT CETP APOE APOC3
28 aortic valve disease 2 31.1 PCSK9 LPA APOB
29 peripheral artery disease 31.1 PCSK9 APOE APOB
30 prediabetes syndrome 31.1 LPL CETP APOB APOA1
31 chronic kidney disease 31.0 LPL LPA LCAT CETP APOB APOA1
32 vascular disease 31.0 LPL LPA CETP APOE APOB APOA2
33 hypoalphalipoproteinemia, primary, 2 31.0 LPA LCAT CETP APOC3 APOB APOA2
34 nonobstructive coronary artery disease 30.9 APOE APOB APOA1
35 peripheral vascular disease 30.9 LPA LCAT CETP APOE APOB APOA1
36 non-alcoholic steatohepatitis 30.9 SCARB1 MTTP APOB
37 abetalipoproteinemia 30.9 TTPA SAR1B MTTP LPL LCAT CETP
38 heart disease 30.9 PCSK9 LPL LPA CETP APOE APOB
39 uremia 30.8 LPL LCAT APOC3
40 chylomicron retention disease 30.7 SAR1B MTTP APOB
41 kidney disease 30.7 LPA LCAT CETP APOE APOC3 APOB
42 coronary heart disease 1 30.7 PCSK9 MTTP LPL LPA LCAT CETP
43 fatty liver disease 30.7 SCARB1 MTTP LPL APOE APOC3 APOB
44 aortic valve disease 1 30.7 LPA APOE APOB APOA1
45 coronary stenosis 30.6 SCARB1 PCSK9 LPL CETP APOE APOB
46 hypobetalipoproteinemia, familial, 2 30.6 SAR1B PCSK9 MTTP LPL LIPG APOC3
47 hypothyroidism 30.6 PCSK9 LPL LPA CETP APOE APOB
48 xanthomatosis 30.6 LPL LPA APOE APOB ABCA1
49 macular degeneration, age-related, 1 30.6 SCARB1 CETP APOE APOB ABCA1
50 nephrotic syndrome 30.5 PCSK9 LPL LPA LCAT CETP APOE

Graphical network of the top 20 diseases related to Hypolipoproteinemia:



Diseases related to Hypolipoproteinemia

Symptoms & Phenotypes for Hypolipoproteinemia

GenomeRNAi Phenotypes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased free cholesterol GR00340-A-2 9.28 APOA1 APOB APOC3 APOE CETP LIPG
2 Increased LDL uptake GR00340-A-1 8.96 APOA1 APOE

MGI Mouse Phenotypes related to Hypolipoproteinemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.97 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOB
2 homeostasis/metabolism MP:0005376 9.91 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
3 cardiovascular system MP:0005385 9.36 ABCA1 ABCG5 APOA1 APOB APOE LCAT

Drugs & Therapeutics for Hypolipoproteinemia

Drugs for Hypolipoproteinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
2
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
3
Dapagliflozin Approved Phase 4 461432-26-8 9887712
4
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
5
Fenofibrate Approved Phase 4 49562-28-9 3339
6
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
7
Methyltestosterone Approved Phase 4 58-18-4 6010
8
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
9
Testosterone enanthate Approved Phase 4 315-37-7 9416
10
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
12
Probucol Approved, Investigational Phase 4 23288-49-5 4912
13 Orange Approved Phase 4
14
Atorvastatin Approved Phase 4 134523-00-5 60823
15
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
16
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
17
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
18
Ezetimibe Approved Phase 4 163222-33-1 150311
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Glimepiride Approved Phase 4 93479-97-1 3476
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
23
Anagliptin Investigational Phase 4 739366-20-2 67068474 44513473
24 Liver Extracts Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Gastrointestinal Agents Phase 4
27 Protective Agents Phase 4
28 Glucagon-Like Peptide 1 Phase 4
29 Calcium, Dietary Phase 4
30 Antioxidants Phase 4
31
Rosuvastatin Calcium Phase 4 147098-20-2
32 Phytosterol Phase 4
33 Androgens Phase 4
34 Testosterone 17 beta-cypionate Phase 4
35 Chrysarobin Phase 4
36 Cardiac Glycosides Phase 4
37 Glycoside Hydrolase Inhibitors Phase 4
38 Colesevelam Hydrochloride Phase 4
39 Anabolic Agents Phase 4
40 Antimetabolites Phase 4
41 Hypolipidemic Agents Phase 4
42 Anticholesteremic Agents Phase 4
43 Lipid Regulating Agents Phase 4
44 Vitamins Phase 4
45 Folate Phase 4
46 Vitamin B9 Phase 4
47 Vitamin B3 Phase 4
48 Trace Elements Phase 4
49 Nicotinic Acids Phase 4
50 Vasodilator Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 278)
# Name Status NCT ID Phase Drugs
1 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
2 Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients Unknown status NCT02280174 Phase 4 linagliptin
3 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
4 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
5 Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes Unknown status NCT03269058 Phase 4 Dapagliflozin;Placebos
6 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
7 Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects Unknown status NCT01301794 Phase 4
8 Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function Completed NCT00298909 Phase 4 niaspan (extended-release niacin);niacin
9 Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration. Completed NCT01321034 Phase 4 Niacin/Laropiprant
10 A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study) Completed NCT00645151 Phase 4 Atorvastatin
11 Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
12 Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome Completed NCT00632840 Phase 4 Atorvastatin and fenofibrate
13 Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111434 Phase 4 Testosterone
14 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
15 12-week, Open-label, Multi-center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL (Low Density Lipoprotein)-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients Completed NCT00747149 Phase 4 Rosuvastatin
16 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
17 Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial Completed NCT02330406 Phase 4 Anagliptin;Sitagliptin
18 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
19 THE EFFECT OF SIMVASTATIN VERSUS COMBINED SIMVASTATIN/EZETIMIBE TREATMENT ON THE CONCENTRATION OF SMALL DENSE LOW-DENSITY LIPOPROTEIN PARTICLES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA Completed NCT00932620 Phase 4 SIMVASTATIN 40 mg;SIMVASTATIN/EZETIMIBE 10/10 mg
20 Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol Completed NCT01122355 Phase 4 lipid modification
21 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
22 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
23 Evaluation of Plant Sterol and Placebo on Low-density Lipoprotein Concentrations in Hyperlipidemic Patients Treated With Combination Statin and Colesevelam Therapy. Completed NCT00249938 Phase 4 Minute Maid Heart Wise orange juice;Welchol
24 The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes Completed NCT00931879 Phase 4 omega-3-ethyl esters;Placebo
25 Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups. Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
26 The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes Completed NCT01384058 Phase 4 ezetimibe;simvastatin;Ezetimibe 10/Simvastatin 20
27 Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes Completed NCT02185963 Phase 4 Rosuvastatin
28 Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood Completed NCT02839902 Phase 4 TAK-085
29 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4 glucagon
30 Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease: a Randomized Comparison Trial Active, not recruiting NCT02579499 Phase 4 fixed high potent statin therapy;targeted LDL-C goal statin
31 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease and/or Type II Diabetes Terminated NCT00651014 Phase 4 Ezetimibe;Placebo
32 Effect of Sitagliptin on Postprandial Lipoprotein Metabolism Terminated NCT00939939 Phase 4 sitagliptin;glimepiride
33 A Pilot Study Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia in Clinical Routine Terminated NCT03559309 Phase 4
34 Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia Terminated NCT01239992 Phase 4 Niacin/ Laropiprant
35 An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia Withdrawn NCT02069106 Phase 4
36 A Study to Determine the Safety and Efficacy in Lipoprotein Lipase-Deficient Subjects After Intramuscular Administration of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein LipaseS447X Unknown status NCT01109498 Phase 2, Phase 3 Mycophenolate mofetil;cyclosporine
37 Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study) Unknown status NCT00633698 Phase 3 Nicotinic acid (niacin);Placebo
38 Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL) Unknown status NCT01286909 Phase 3
39 ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) Completed NCT02658175 Phase 3 Volanesorsen
40 An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects Completed NCT00891306 Phase 2, Phase 3 mycophenolate mofetil;cyclosporine;methylprednisolone
41 Combined Effects of Bioactive Compounds (ARMOLIPID PLUS ®) on Lipid Profile and Clinical Criteria of Metabolic Syndrome in Patients With Serum Elevated LDL-C Completed NCT01562080 Phase 2, Phase 3
42 Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Completed NCT01958775 Phase 3 GLP-2;Placebo
43 A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Effects of Sitagliptin on Postprandial Plasma Lipoprotein Concentrations in Men With Type 2 Diabetes Completed NCT00660075 Phase 3 Sitagliptin;Placebo
44 A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment Completed NCT02585895 Phase 3
45 A 72-week, Prospective, Parallel-group, Partially Blinded, Controlled Phase IIIb Study Evaluating the Impact of Specific Lp(a) Apheresis on Atherosclerotic Disease Burden in Coronary Heart Disease Patients With High Lipoprotein(a) Level. Completed NCT02133807 Phase 3
46 A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c) Completed NCT00551447 Phase 3 MK0653, ezetimibe / Duration of Treatment: 27 Weeks;MK0733, simvastatin / Duration of Treatment: 27 Weeks;Comparator: simvastatin / Duration of Treatment: 27 Weeks
47 Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity Completed NCT00438061 Phase 3
48 Phase 3 Study; Effects of Green Tea Extract on Obese Women With High Level of Low Density Lipoprotein (LDL): a Randomized, Double-blinded, and Cross-over Placebo-controlled Clinical Trial Completed NCT02116517 Phase 3
49 Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity Completed NCT00392717 Phase 3 Atorvastatin;Fish oils
50 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease. Completed NCT00092638 Phase 3 MK0653, ezetimibe;Comparator: ezetimibe, placebo

Search NIH Clinical Center for Hypolipoproteinemia

Cochrane evidence based reviews: hypolipoproteinemias

Genetic Tests for Hypolipoproteinemia

Anatomical Context for Hypolipoproteinemia

Organs/tissues related to Hypolipoproteinemia:

MalaCards : Liver, Heart, Thyroid, Endothelial, Smooth Muscle, Bone Marrow, Skeletal Muscle

Publications for Hypolipoproteinemia

Articles related to Hypolipoproteinemia:

(show top 50) (show all 30203)
# Title Authors PMID Year
1
Expression pattern and raft association of NIPSNAP3 and NIPSNAP4, highly homologous proteins encoded by genes in close proximity to the ATP-binding cassette transporter A1. 53 62
15177564 2004
2
Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. 53 62
15019541 2004
3
ATP-binding cassette (ABC) transporters in human metabolism and diseases. 53 62
15209530 2004
4
Expression, regulation, and activity of ABCA1 in human cell lines. 53 62
12706378 2003
5
Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? 53 62
11861429 2002
6
Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency. 53 62
11785958 2002
7
Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome. 53 62
11476961 2001
8
High-density single-nucleotide polymorphism (SNP) map of the 150-kb region corresponding to the human ATP-binding cassette transporter A1 (ABCA1) gene. 53 62
11558901 2001
9
Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. 53 62
9401010 1997
10
Suppressive effects of the endothelin receptor (ETA) antagonist BQ-123 on ET-1-induced reduction of lipoprotein lipase activity in 3T3-L1 adipocytes. 53 62
1417963 1992
11
The role of apolipoprotein E genetic variants in lipoprotein disorders. 53 62
1619388 1992
12
Low-density lipoprotein encapsulated thiosemicarbazone metal complexes is active targeting vehicle for breast, lung, and prostate cancers. 62
35815732 2022
13
Myristicin regulates proliferation and apoptosis in oxidized low-density lipoprotein-stimulated human vascular smooth muscle cells and human umbilical vein endothelial cells by regulating the PI3K/Akt/NF-κB signalling pathway. 62
34905418 2022
14
Serum Lipids and Risk of Incident Psoriasis: A Prospective Cohort Study from the UK Biobank Study and Mendelian Randomization Analysis. 62
35850211 2022
15
Differences in the Distribution of Ceramides and Sphingosine among Lipoprotein and Lipoprotein-Depleted Fractions in Patients with Type 2 Diabetes Mellitus. 62
35082227 2022
16
Metabolomic profiling for dyslipidemia in pediatric patients with sickle cell disease, on behalf of the IHCC consortium. 62
36459297 2022
17
Two Cases of Acquired High-Density Lipoprotein Deficiency with Immunoglobulin G4-Related Lecithin-Cholesterol Acyltransferase Autoantibody. 62
36384970 2022
18
Association between high oxidized high-density lipoprotein levels and increased pericoronary inflammation determined by coronary computed tomography angiography. 62
35853799 2022
19
Letter by Lakshmanan et al Regarding Article "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy". 62
36374969 2022
20
Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy". 62
36374970 2022
21
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? 62
34849601 2022
22
Relationship Between Relative Grip Strength and Serum Total Cholesterol, High-Density Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, and Triglyceride Levels in Korean Middle-Aged or Older Adults: A Panel Regression Model. 62
36322887 2022
23
High-Density Lipoprotein Suppresses Neutrophil Extracellular Traps Enhanced by Oxidized Low-Density Lipoprotein or Oxidized Phospholipids. 62
36430470 2022
24
Impact of High-Density Lipoprotein Function, Rather Than High-Density Lipoprotein Cholesterol Level, on Cardiovascular Disease Among Patients With Familial Hypercholesterolemia. 62
36436874 2022
25
Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease. 62
36423994 2022
26
Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer. 62
34897572 2022
27
High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients. 62
35968698 2022
28
Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting. 62
36149672 2022
29
Neutrophil to high-density lipoprotein ratio associates with higher all-cause mortality and new onset cardiovascular events in peritoneal dialysis patients. 62
35411415 2022
30
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. 62
36175048 2022
31
Effects of general and central adiposity on circulating lipoprotein, lipid, and metabolite levels in UK Biobank: A multivariable Mendelian randomization study. 62
35832062 2022
32
Impact of different training modalities on high-density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial. 62
35747946 2022
33
Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease. 62
34880156 2022
34
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. 62
36036785 2022
35
High-Density Lipoprotein and Long-Term Incidence and Progression of Aortic Valve Calcification: The Multi-Ethnic Study of Atherosclerosis. 62
35979837 2022
36
The role of hepatic Surf4 in lipoprotein metabolism and the development of atherosclerosis in apoE-/- mice. 62
35803528 2022
37
Lipoprotein-X and Lipoprotein-Z Induced Hyperviscosity Syndrome in the Setting of Cholestatic Liver Failure. 62
36299645 2022
38
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity. 62
35676229 2022
39
Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). 62
36253168 2022
40
The clinical significance of preoperative serum triglyceride, high-density lipoprotein, and low-density lipoprotein levels in lung squamous cell carcinoma. 62
36207435 2022
41
[Lipoprotein(a) - the unknown lipoprotein]. 62
36198968 2022
42
Effect of lipoprotein (a) on the analytical determination of low-density lipoprotein cholesterol (LDLc) and its influence on pharmacological treatment with atorvastatin. 62
36200772 2022
43
The association between low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio cholesterol ratio and thickened carotid intima-media thickness: A case-control study. 62
34311590 2022
44
Association between triglyceride-to-high-density lipoprotein cholesterol ratio and prediabetes: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol. 62
36273126 2022
45
Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. 62
36216435 2022
46
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). 62
35588897 2022
47
Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease: The Japan Epidemiology Collaboration on Occupational Health Study. 62
34690212 2022
48
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. 62
36068139 2022
49
Association of lipoprotein(a) with aortic dissection. 62
35925003 2022
50
Possible association of high-density lipoprotein cholesterol levels with trunk muscle deficits and decrease in energy expenditure in patients with or at risk for COPD: A pilot study. 62
35821189 2022

Variations for Hypolipoproteinemia

Expression for Hypolipoproteinemia

Search GEO for disease gene expression data for Hypolipoproteinemia.

Pathways for Hypolipoproteinemia

Pathways related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 TTPA SAR1B LPL APOE APOC3 APOB
2
Show member pathways
13.34 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
3
Show member pathways
12.86 CETP APOE ANGPTL3 ABCG5 ABCG1 ABCA1
4
Show member pathways
12.67 TTPA LPL APOE APOC3 APOB APOA2
5
Show member pathways
12.56 ABCA1 ABCG1 ANGPTL3 APOA1 APOA2 APOB
6
Show member pathways
12.49 TTPA LPL APOE APOC3 APOB APOA2
7
Show member pathways
12.37 LPL APOA2 APOA1 ABCA1
8
Show member pathways
12.28 APOA1 APOA2 APOB APOE PCSK9
9
Show member pathways
11.87 CETP APOE ANGPTL3 ABCG5 ABCG1 ABCA1
10
Show member pathways
11.75 SCARB1 APOE APOB APOA1
11
Show member pathways
11.72 LPL APOC3 APOA2 APOA1
12
Show member pathways
11.65 ABCA1 ABCG5 APOA1 APOA2 APOB APOC3
13 11.34 SCARB1 LPL ABCG5
14 11.28 MIR33A ABCG5 ABCG1 ABCA1
15 11.12 APOC3 APOA2 APOA1
16
Show member pathways
11.12 ANGPTL3 APOA1 APOA2 APOB CETP LCAT
17 10.95 ABCA1 ABCG1 APOA1 APOA2
18 10.88 MTTP APOB
19 10.83 SCARB1 ABCG5

GO Terms for Hypolipoproteinemia

Cellular components related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.56 PCSK9 LPL LPA LIPG LCAT CETP
2 extracellular space GO:0005615 10.46 ANGPTL3 APOA1 APOA2 APOB APOC3 APOE
3 endoplasmic reticulum lumen GO:0005788 10.23 APOA1 APOA2 APOB APOE MTTP PCSK9
4 early endosome GO:0005769 10.16 ANGPTL3 APOA1 APOA2 APOB APOC3 APOE
5 high-density lipoprotein particle GO:0034364 9.93 LCAT CETP APOE APOB APOA2 APOA1
6 endocytic vesicle lumen GO:0071682 9.91 APOE APOB APOA1
7 spherical high-density lipoprotein particle GO:0034366 9.85 APOC3 APOA2 APOA1
8 intermediate-density lipoprotein particle GO:0034363 9.8 APOE APOC3 APOB
9 very-low-density lipoprotein particle GO:0034361 9.73 APOA1 APOA2 APOB APOC3 APOE LPL
10 chylomicron GO:0042627 9.4 LPL APOE APOC3 APOB APOA2 APOA1

Biological processes related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 cholesterol homeostasis GO:0042632 10.57 ABCA1 ABCG1 ABCG5 ANGPTL3 APOA1 APOA2
2 lipid metabolic process GO:0006629 10.45 ABCA1 ANGPTL3 APOA1 APOB APOC3 APOE
3 cholesterol metabolic process GO:0008203 10.43 ABCA1 ABCG1 ANGPTL3 APOA1 APOA2 APOB
4 reverse cholesterol transport GO:0043691 10.4 ABCA1 ABCG1 APOA1 APOA2 APOC3 APOE
5 triglyceride metabolic process GO:0006641 10.37 PCSK9 MTTP LPL CETP APOE APOC3
6 phospholipid homeostasis GO:0055091 10.33 ABCA1 ABCG1 ANGPTL3 APOA1 CETP LIPG
7 lipid transport GO:0006869 10.33 LPA MTTP SCARB1 ABCA1 ABCG1 ABCG5
8 low-density lipoprotein particle remodeling GO:0034374 10.31 MTTP CETP APOE APOB APOA2 ABCG1
9 phospholipid efflux GO:0033700 10.29 ABCA1 ABCG1 APOA1 APOA2 APOC3 APOE
10 high-density lipoprotein particle remodeling GO:0034375 10.28 APOC3 APOE CETP LCAT LIPG SCARB1
11 very-low-density lipoprotein particle remodeling GO:0034372 10.27 LPL LCAT CETP APOE APOA1
12 cholesterol transport GO:0030301 10.27 SCARB1 LCAT CETP APOB APOA2 APOA1
13 phospholipid metabolic process GO:0006644 10.26 ANGPTL3 APOA1 LCAT LPL PCSK9
14 positive regulation of cholesterol efflux GO:0010875 10.22 APOE APOA1 ABCG1 ABCA1
15 triglyceride catabolic process GO:0019433 10.21 LPL LIPG APOC3 APOB
16 lipoprotein biosynthetic process GO:0042158 10.21 LCAT APOE APOB APOA1 ABCA1
17 high-density lipoprotein particle assembly GO:0034380 10.2 APOE APOA2 APOA1 ABCA1
18 lipid homeostasis GO:0055088 10.19 SAR1B CETP APOE ANGPTL3
19 regulation of Cdc42 protein signal transduction GO:0032489 10.19 APOE APOC3 APOA1 ABCA1
20 high-density lipoprotein particle clearance GO:0034384 10.19 SCARB1 APOE APOA2 APOA1
21 phospholipid transport GO:0015914 10.17 SCARB1 MTTP CETP
22 lipid catabolic process GO:0016042 10.16 APOB APOC3 LIPG LPL
23 artery morphogenesis GO:0048844 10.15 APOE APOB ANGPTL3
24 phosphatidylcholine biosynthetic process GO:0006656 10.14 LCAT APOA2 APOA1
25 phosphatidylcholine metabolic process GO:0046470 10.14 LCAT CETP APOA1
26 phospholipid catabolic process GO:0009395 10.13 ANGPTL3 APOA2 LIPG
27 lipoprotein transport GO:0042953 10.13 SAR1B MTTP APOB
28 negative regulation of macrophage derived foam cell differentiation GO:0010745 10.12 CETP ABCG1 ABCA1
29 steroid metabolic process GO:0008202 10.12 ABCA1 APOA1 APOB APOE CETP LCAT
30 very-low-density lipoprotein particle assembly GO:0034379 10.11 MTTP APOC3 APOB
31 positive regulation of CoA-transferase activity GO:1905920 10.11 APOA1 APOA2 APOE
32 positive regulation of cholesterol storage GO:0010886 10.1 SCARB1 LPL APOB
33 lipoprotein metabolic process GO:0042157 10.1 ABCA1 APOA1 APOA2 APOB APOC3 APOE
34 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 10.09 APOC3 APOA2 APOA1
35 triglyceride homeostasis GO:0070328 10.09 ABCG5 ANGPTL3 APOA1 APOC3 APOE CETP
36 negative regulation of low-density lipoprotein particle clearance GO:0010989 10.03 PCSK9 APOC3
37 negative regulation of cholesterol storage GO:0010887 10.03 ABCG1 ABCA1
38 cholesterol catabolic process GO:0006707 10.02 SCARB1 APOE
39 positive regulation of amyloid-beta clearance GO:1900223 10.02 TTPA APOE
40 positive regulation of lipid catabolic process GO:0050996 10.02 APOA2 ANGPTL3
41 negative regulation of lipoprotein lipase activity GO:0051005 10.02 ANGPTL3 APOC3
42 vitamin transport GO:0051180 10.02 APOA1 TTPA
43 cholesterol import GO:0070508 10.01 APOA1 SCARB1
44 positive regulation of cholesterol transport GO:0032376 10.01 LIPG CETP
45 peptidyl-methionine modification GO:0018206 10.01 APOA2 APOA1
46 negative regulation of cytokine production involved in immune response GO:0002719 10.01 APOA2 APOA1
47 regulation of intestinal cholesterol absorption GO:0030300 10 APOA1 APOA2
48 chylomicron remnant clearance GO:0034382 10 APOC3 APOE
49 lipoprotein catabolic process GO:0042159 10 APOB APOE
50 positive regulation of cholesterol metabolic process GO:0090205 9.99 APOA1 APOE

Molecular functions related to Hypolipoproteinemia according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 10.39 LPL LPA APOE APOA2 APOA1 ANGPTL3
2 heparin binding GO:0008201 10.27 ANGPTL3 APOB APOE LIPG LPA LPL
3 phospholipid binding GO:0005543 10.15 APOE APOC3 APOB APOA2 APOA1 ABCG1
4 lipid binding GO:0008289 10.13 APOA1 APOA2 APOC3 APOE CETP MTTP
5 phosphatidylcholine binding GO:0031210 10.11 CETP APOA2 APOA1 ABCA1
6 ATPase-coupled transmembrane transporter activity GO:0042626 10.09 ABCA1 ABCG1 ABCG5
7 low-density lipoprotein particle receptor binding GO:0050750 10.04 APOB APOE PCSK9
8 phospholipid transporter activity GO:0005548 10.03 MTTP CETP ABCA1
9 cholesterol binding GO:0015485 10.03 CETP APOC3 APOA2 APOA1 ABCG1 ABCA1
10 high-density lipoprotein particle binding GO:0008035 10.01 APOA1 APOA2 SCARB1
11 ABC-type transporter activity GO:0140359 9.99 ABCG5 ABCG1 ABCA1
12 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.95 APOE APOA2 APOA1
13 phosphatidylserine 1-acylhydrolase activity GO:0052739 9.94 LPL LIPG
14 lipoprotein lipase activity GO:0004465 9.93 LPL LIPG
15 1-acyl-2-lysophosphatidylserine acylhydrolase activity GO:0052740 9.93 LPL LIPG
16 apolipoprotein A-I binding GO:0034186 9.93 SCARB1 LCAT ABCA1
17 phosphatidylcholine floppase activity GO:0090554 9.92 ABCG1 ABCA1
18 lipoprotein particle binding GO:0071813 9.92 LPL APOE APOA1
19 lipase inhibitor activity GO:0055102 9.91 APOC3 APOA2
20 apolipoprotein receptor binding GO:0034190 9.91 APOA1 APOA2 PCSK9
21 triglyceride binding GO:0017129 9.9 LPL CETP
22 floppase activity GO:0140328 9.88 ABCG1 ABCA1
23 very-low-density lipoprotein particle receptor binding GO:0070326 9.88 PCSK9 APOE
24 high-density lipoprotein particle receptor binding GO:0070653 9.88 APOA1 APOA2 APOC3
25 lipid transporter activity GO:0005319 9.85 MTTP APOE APOB APOA2 APOA1 ABCA1
26 lipid transfer activity GO:0120013 9.79 TTPA MTTP
27 apolipoprotein binding GO:0034185 9.73 ABCA1 LPA LPL MTTP PCSK9 SCARB1
28 cholesterol transfer activity GO:0120020 9.58 MTTP CETP APOE APOB APOA2 APOA1

Sources for Hypolipoproteinemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....